 |
09.14.2009
David Ebersman Joins Ironwood Board of Directors
|
12.2 KB |
| |
CAMBRIDGE, Mass., September 14, 2009 - Ironwood Pharmaceuticals, Inc. today announced that David Ebersman has joined the Company's Board of Directors. Mr. Ebersman is the chief financial officer of Facebook. He served at Genentech from 1994-2009 in a number of senior positions, including executive vice president and chief financial office...
|
|
05.31.2009
Ironwood And Forest Present Additional Positive Phase 2b Study Results For Linaclotide In Patients With Irritable Bowel Syndrome With Constipation
|
20.7 KB |
| |
CAMBRIDGE, Mass. and New York, May 31, 2009 - Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced results from additional analyses of their Phase 2b study assessing the safety and efficacy of the novel, first-in-class agent linaclotide in 419 patients with irritable bowel syndrome with constipation (...
|
|
05.12.2009
Ironwood And Forest To Present Additional Phase 2b Data For Novel Gastrointestinal Agent Linaclotide
|
17.7 KB |
| |
CAMBRIDGE, Mass. and New York, May 12, 2009 - Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be reporting additional clinical data from their Phase 2b studies for linaclotide, a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS...
|
|
05.04.2009
Ironwood Announces Linaclotide European Licensing Agreement With Almirall
|
15.9 KB |
| |
CAMBRIDGE, Mass., May 4, 2009 - Ironwood Pharmaceuticals, Inc. today announced that the company has entered into an out-licensing agreement with Laboratorios Almirall, S.A. for European rights to develop and commercialize the investigational compound linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and...
|
| |
10.21.2008
Ironwood Presents Positive Phase 2b Study Results for Linaclotide in Patients with Irritable Bowel Syndrome with Constipation
|
137.5 KB |
|
|
